FASN and carcinoma: FASN is overexpressed in a variety of human carcinomas [8,9], including TNBC [28], and its inhibition with polyphenolic compounds such as EGCG has been demonstrated to be a promising therapeutic strategy, alone and in combination, for TNBC [13].